Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

KHNYN is essential for the zinc finger antiviral protein (ZAP) to restrict HIV-1 containing clustered CpG dinucleotides.

Ficarelli M, Wilson H, Pedro Galão R, Mazzon M, Antzin-Anduetza I, Marsh M, Neil SJ, Swanson CM.

Elife. 2019 Jul 9;8. pii: e46767. doi: 10.7554/eLife.46767.

2.

Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses.

Prévost J, Pickering S, Mumby MJ, Medjahed H, Gendron-Lepage G, Delgado GG, Dirk BS, Dikeakos JD, Stürzel CM, Sauter D, Kirchhoff F, Bibollet-Ruche F, Hahn BH, Dubé M, Kaufmann DE, Neil SJD, Finzi A, Richard J.

MBio. 2019 Jun 18;10(3). pii: e01113-19. doi: 10.1128/mBio.01113-19.

3.

Adeno-associated virus Rep proteins antagonize phosphatase PP1 to counteract KAP1 repression of the latent viral genome.

Smith-Moore S, Neil SJD, Fraefel C, Linden RM, Bollen M, Rowe HM, Henckaerts E.

Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3529-E3538. doi: 10.1073/pnas.1721883115. Epub 2018 Mar 26.

4.

Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane.

Foster TL, Pickering S, Neil SJD.

Front Immunol. 2018 Jan 4;8:1853. doi: 10.3389/fimmu.2017.01853. eCollection 2017. Review.

5.

Sensitivity to BST-2 restriction correlates with Orthobunyavirus host range.

Varela M, Piras IM, Mullan C, Shi X, Tilston-Lunel NL, Pinto RM, Taggart A, Welch SR, Neil SJD, Kreher F, Elliott RM, Palmarini M.

Virology. 2017 Sep;509:121-130. doi: 10.1016/j.virol.2017.06.017. Epub 2017 Jun 17.

6.

BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH, Kaufmann DE, Smith AB 3rd, Sodroski J, Sauter D, Kirchhoff F, Gee K, Neil SJ, Evans DT, Finzi A.

J Virol. 2017 May 12;91(11). pii: e00219-17. doi: 10.1128/JVI.00219-17. Print 2017 Jun 1.

7.

Exercising Restraint.

Neil SJ.

Cell Host Microbe. 2017 Mar 8;21(3):274-277. doi: 10.1016/j.chom.2017.01.008.

8.

A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages.

Mlcochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RA, Rehwinkel J, Neil SJ, Lenzi GM, Kim B, Khwaja A, Gage MC, Georgiou C, Chittka A, Yona S, Noursadeghi M, Towers GJ, Gupta RK.

EMBO J. 2017 Mar 1;36(5):604-616. doi: 10.15252/embj.201696025. Epub 2017 Jan 25.

9.

The Envelope Gene of Transmitted HIV-1 Resists a Late Interferon Gamma-Induced Block.

Rihn SJ, Foster TL, Busnadiego I, Aziz MA, Hughes J, Neil SJD, Wilson SJ.

J Virol. 2017 Mar 13;91(7). pii: e02254-16. doi: 10.1128/JVI.02254-16. Print 2017 Apr 1.

10.

Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction.

Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, Kellam P, Finzi A, Borrow P, Hahn BH, Neil SJD.

Cell Host Microbe. 2016 Oct 12;20(4):429-442. doi: 10.1016/j.chom.2016.08.006. Epub 2016 Sep 15.

11.

Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef.

Matheson NJ, Sumner J, Wals K, Rapiteanu R, Weekes MP, Vigan R, Weinelt J, Schindler M, Antrobus R, Costa AS, Frezza C, Clish CB, Neil SJ, Lehner PJ.

Cell Host Microbe. 2015 Oct 14;18(4):409-23. doi: 10.1016/j.chom.2015.09.003. Epub 2015 Oct 1.

12.

Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors.

Kueck T, Foster TL, Weinelt J, Sumner JC, Pickering S, Neil SJ.

PLoS Pathog. 2015 Aug 28;11(8):e1005141. doi: 10.1371/journal.ppat.1005141. eCollection 2015 Aug.

13.

G2/M cell cycle arrest correlates with primate lentiviral Vpr interaction with the SLX4 complex.

Berger G, Lawrence M, Hué S, Neil SJ.

J Virol. 2015 Jan;89(1):230-40. doi: 10.1128/JVI.02307-14. Epub 2014 Oct 15.

14.

Retroviral retention activates a Syk-dependent HemITAM in human tetherin.

Galão RP, Pickering S, Curnock R, Neil SJ.

Cell Host Microbe. 2014 Sep 10;16(3):291-303. doi: 10.1016/j.chom.2014.08.005.

15.

Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses.

Weinelt J, Neil SJ.

J Virol. 2014 May;88(10):5845-58. doi: 10.1128/JVI.03818-13. Epub 2014 Mar 12.

16.

Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals.

Pickering S, Hué S, Kim EY, Reddy S, Wolinsky SM, Neil SJ.

PLoS Pathog. 2014 Jan;10(1):e1003895. doi: 10.1371/journal.ppat.1003895. Epub 2014 Jan 23. Erratum in: PLoS Pathog. 2014 Apr;10(4):e1004118.

17.

The antiviral activities of tetherin.

Neil SJ.

Curr Top Microbiol Immunol. 2013;371:67-104. doi: 10.1007/978-3-642-37765-5_3. Review.

PMID:
23686232
18.

Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection.

Goujon C, Schaller T, Galão RP, Amie SM, Kim B, Olivieri K, Neil SJ, Malim MH.

Retrovirology. 2013 Feb 25;10:23. doi: 10.1186/1742-4690-10-23.

19.

Ig-like transcript 7, but not bone marrow stromal cell antigen 2 (also known as HM1.24, tetherin, or CD317), modulates plasmacytoid dendritic cell function in primary human blood leukocytes.

Tavano B, Galao RP, Graham DR, Neil SJ, Aquino VN, Fuchs D, Boasso A.

J Immunol. 2013 Mar 15;190(6):2622-30. doi: 10.4049/jimmunol.1202391. Epub 2013 Feb 11.

20.

Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses.

Galão RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ.

Cell Host Microbe. 2012 Nov 15;12(5):633-44. doi: 10.1016/j.chom.2012.10.007.

21.
22.

The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a SOUBA domain.

Agromayor M, Soler N, Caballe A, Kueck T, Freund SM, Allen MD, Bycroft M, Perisic O, Ye Y, McDonald B, Scheel H, Hofmann K, Neil SJ, Martin-Serrano J, Williams RL.

Structure. 2012 Mar 7;20(3):414-28. doi: 10.1016/j.str.2011.12.013.

23.

Release of filamentous and spherical influenza A virus is not restricted by tetherin.

Bruce EA, Abbink TE, Wise HM, Rollason R, Galao RP, Banting G, Neil SJ, Digard P.

J Gen Virol. 2012 May;93(Pt 5):963-9. doi: 10.1099/vir.0.038778-0. Epub 2012 Jan 18.

PMID:
22258861
24.

Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction.

Le Tortorec A, Willey S, Neil SJ.

Viruses. 2011 May;3(5):520-40. doi: 10.3390/v3050520. Epub 2011 May 6. Review.

25.
26.

Host factors involved in retroviral budding and release.

Martin-Serrano J, Neil SJ.

Nat Rev Microbiol. 2011 Jun 16;9(7):519-31. doi: 10.1038/nrmicro2596. Review.

PMID:
21677686
27.

Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Willey S, Aasa-Chapman MM, O'Farrell S, Pellegrino P, Williams I, Weiss RA, Neil SJ.

Retrovirology. 2011 Mar 14;8:16. doi: 10.1186/1742-4690-8-16.

28.

Identification of a receptor for an extinct virus.

Soll SJ, Neil SJ, Bieniasz PD.

Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19496-501. doi: 10.1073/pnas.1012344107. Epub 2010 Oct 25.

29.

Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Vigan R, Neil SJ.

J Virol. 2010 Dec;84(24):12958-70. doi: 10.1128/JVI.01699-10. Epub 2010 Oct 6.

30.

Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.

Jolly C, Booth NJ, Neil SJ.

J Virol. 2010 Dec;84(23):12185-99. doi: 10.1128/JVI.01447-10. Epub 2010 Sep 22.

31.

The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.

Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P, Kellam P, Towers GJ, Neil SJ.

PLoS Pathog. 2010 Apr 15;6(4):e1000843. doi: 10.1371/journal.ppat.1000843.

32.

Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors.

Groom HC, Yap MW, Galão RP, Neil SJ, Bishop KN.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5166-71. doi: 10.1073/pnas.0913650107. Epub 2010 Mar 1.

33.

Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses.

Arnaud F, Black SG, Murphy L, Griffiths DJ, Neil SJ, Spencer TE, Palmarini M.

J Virol. 2010 May;84(9):4415-25. doi: 10.1128/JVI.00029-10. Epub 2010 Feb 24.

34.

Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.

Le Tortorec A, Neil SJ.

J Virol. 2009 Nov;83(22):11966-78. doi: 10.1128/JVI.01515-09. Epub 2009 Sep 9.

35.

Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.

McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD.

PLoS Pathog. 2009 Feb;5(2):e1000300. doi: 10.1371/journal.ppat.1000300. Epub 2009 Feb 13.

36.

Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.

Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD.

J Virol. 2009 Feb;83(4):1837-44. doi: 10.1128/JVI.02211-08. Epub 2008 Nov 26.

37.

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Neil SJ, Zang T, Bieniasz PD.

Nature. 2008 Jan 24;451(7177):425-30. doi: 10.1038/nature06553. Epub 2008 Jan 16.

PMID:
18200009
38.
39.

Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.

Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB.

FEBS J. 2007 Sep;274(17):4511-25. Epub 2007 Aug 6.

40.

Plasma membrane is the site of productive HIV-1 particle assembly.

Jouvenet N, Neil SJ, Bess C, Johnson MC, Virgen CA, Simon SM, Bieniasz PD.

PLoS Biol. 2006 Dec;4(12):e435. Erratum in: PLoS Biol. 2018 Nov 16;16(11):e3000078.

41.

HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.

Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD.

PLoS Pathog. 2006 May;2(5):e39. Epub 2006 May 12.

42.
43.
45.

HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation.

Neil SJ, McKnight A, Gustafsson K, Weiss RA.

Blood. 2005 Jun 15;105(12):4693-9. Epub 2005 Feb 22.

PMID:
15728127
46.

Lv2, a novel postentry restriction, is mediated by both capsid and envelope.

Schmitz C, Marchant D, Neil SJ, Aubin K, Reuter S, Dittmar MT, McKnight A.

J Virol. 2004 Feb;78(4):2006-16.

47.

Targeted retroviral infection of tumor cells by receptor cooperation.

Martin F, Chowdhury S, Neil SJ, Chester KA, Cosset FL, Collins MK.

J Virol. 2003 Feb;77(4):2753-6.

Supplemental Content

Support Center